1.KASL guideline of managent of chronic hepatitis C.
Korean Journal of Medicine 2005;69(6):713-717
No abstract available.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
2.Current therapy for chronic hepatitis C.
Journal of the Korean Academy of Family Medicine 2000;21(11):1383-1394
No Abstract Available.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
3.Standard treatment of Chronic hepatitis C.
Korean Journal of Medicine 2005;68(3):251-255
No abstract available.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
4.Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy.
Gut and Liver 2017;11(6):745-746
No abstract available.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
5.Chronic Hepatitis C Virus Infection, Why Not Treat Now?.
Journal of Rheumatic Diseases 2018;25(3):151-152
No abstract available.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
6.What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Journal of Korean Medical Science 2019;34(41):e277-
No abstract available.
Hepatitis C, Chronic
;
Hepatitis, Chronic
8.Peginterferon Alfa-2a on Patients with Chronic Hepatitis C.
The Korean Journal of Hepatology 2001;7(1):107-109
No abstract availalbe.
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
;
Humans
9.Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals.
The Korean Journal of Gastroenterology 2017;70(2):111-113
No abstract available.
Antiviral Agents*
;
Hepatitis C, Chronic*
;
Hepatitis, Chronic*
10.Regional Diversity of Hepatitis C Virus Prevalence: Seeking for Culture Specific Mode of Transmission.
Gut and Liver 2014;8(4):337-338
No abstract available.
Hepatitis C, Chronic/*epidemiology
;
Humans
Result Analysis
Print
Save
E-mail